Manareco New Materials announced that its wholly-owned subsidiary, Ruilian Pharmaceutical, recently received the Drug GMP Compliance Inspection Notification issued by the Shaanxi Provincial Drug Administration. The active pharmaceutical ingredient posaconazole produced at its production base in the high-tech industrial development zone of Weinan City has passed the GMP Compliance Inspection and meets the requirements of the Pharmaceutical Production Quality Management Specification.
瑞联新材：全资子公司通过药品GMP符合性检查
Xi'an ManaReco New Materials: Wholly-owned subsidiary passes pharmaceutical GMP compliance inspection.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.